Brief: Astellas Says Co And 4D Molecular Therapeutics (4DMT) Have Entered Into License Agreement To Use 4DMT's Proprietary Intravitreal R100 Vector For Rare Ophthalmic Targets

4D Molecular Therapeutics

11/07/2023 24:32

July 10 (Reuters) - Astellas Pharma Inc  4503.T :
    * ASTELLAS AND 4D MOLECULAR THERAPEUTICS (4DMT) ENTER INTO
LICENSE
AGREEMENT TO USE 4DMT'S PROPRIETARY INTRAVITREAL R100 VECTOR FOR
RARE OPHTHALMIC TARGETS
    * ASTELLAS PHARMA- 4DMT WILL RECEIVE US$20 MILLION UPFRONT,
AND
POTENTIAL FUTURE OPTION FEES AND MILESTONES OF UP TO US$942.5
MILLION
    * ASTELLAS - 4DMT IS ENTITLED TO RECEIVE MID-SINGLE DIGIT TO
DOUBLE-DIGIT, SUB-TEEN ROYALTIES ON NET SALES OF ALL LICENSED
PRODUCTS

Source text for Eikon:  ID:nPnbX9XCwa 
Further company coverage:  4503.T 

 ((Reuters.Briefs@thomsonreuters.com;))